Perimenopausin

Perimenopausin is a term occasionally used in speculative or exploratory discussions to refer to a putative molecular signal associated with the perimenopausal transition. It is not established as a defined hormone or validated biomarker in major medical guidelines, and evidence for its existence remains limited and controversial. The concept emerged from efforts to identify molecular correlates of the shift from regular cycles to amenorrhea, vasomotor symptoms, and other features of perimenopause.

Proposed sources include ovarian or hypothalamic–pituitary tissues, with perimenopausin posited to influence hypothalamic drive, ovarian follicle dynamics, or vascular regulation. In theory, changing levels could track with the onset of perimenopausal symptoms, but the precise biology is unknown, and no receptor or signaling pathway has been clearly demonstrated.

Current reports are preliminary and often based on small cohorts or preclinical models. Assays described in the literature are not standardized, and findings are not reproducible across laboratories. There is no validated clinical test or cutoffs, and guidelines do not recommend use of perimenopausin testing for diagnosis or management.

If proven, perimenopausin could potentially help predict timing of menopause, differentiate perimenopause from other causes of symptoms, or guide hormone therapy decisions; however, substantial, well-controlled research is required to establish validity, specificity, and clinical utility. Observed correlations may reflect unrelated inflammatory or metabolic processes rather than a causal role.

See also: perimenopause, menopause, biomarkers.